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Glucocorticoid receptors, in vitro steroid sensitivity, and cy-
tokine secretion in idiopathic nephrotic syndrome.
Background. Glucocorticoids (GC) represent the mainstay
of treatment of idiopathic nephrotic syndrome (INS) and
might be involved in the pathogenesis of the disease. We
evaluated basal secretion of cortisol, number and affinity of
glucocorticoid receptors, dexamethasone (Dex)-mediated inhi-
bition of concanavalin-A (Con-A)–stimulated peripheral blood
mononuclear cell (PBMC) proliferation, and cytokine secretion
in patients with INS.
Methods. Blood and saliva were obtained from 20 INS pa-
tients in relapse and 11 control patients. Cortisol concentrations
were measured by radioimmunoassay. PBMC were isolated for
binding and in vitro GC sensitivity assays. Cytokines were mea-
sured in supernatants of PBMC culture by enzyme-linked im-
munosorbent assay (ELISA).
Results. Salivary cortisol concentrations were similar in INS
patients and control patients. Density and affinity of GC recep-
tors were similar in steroid-sensitive (SS) patients and control,
whereas in steroid-resistant (SR) patients they were variable.
Lymphocyte proliferation after Con-A stimulation was inhib-
ited by Dex in a dose-dependent manner in control and SS
patients. Control and all clinically SS patients were steroid-
sensitive by in vitro test, but control patients significantly pre-
sented more suppression of PBMC proliferation compared with
SS patients. Basal- and Con-A–stimulated interleukin (IL)-6,
IL-10, interferon (IFN)-c , and tumor necrosis factor (TNF)-a
levels were similar in control and INS patients, and all cytokines
but IL-10 were significantly inhibited by Dex 10−6 mol/L. In SR
patients, cytokine secretion remained elevated after treatment
with high doses of Dex.
Conclusion. Abnormalities of number and affinity of the GC
receptor and altered secretion of cytokines may be involved in
tissue sensitivity to GC in INS patients.
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tokines, in vitro steroid sensitivity, idiopathic nephrotic syndrome.
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Steroid responsiveness is the major determinant of
prognosis in idiopathic nephrotic syndrome (INS). Ap-
proximately 85% to 90% of patients with INS respond
to glucocorticoid (GC) therapy and have complete re-
mission of proteinuria; 10% to 15% have partial or no
response to corticosteroid treatment [1]. Children with
steroid-sensitive (SS) INS have a favorable long-term
outcome, even after multiple relapses, whereas 50% of
steroid-resistant (SR) patients progress to end-stage re-
nal failure within 1 to 4 years [2]. There are no clinical
predictors of the response to corticosteroids in INS.
The etiology of INS remains obscure. Cellular im-
mune disturbances, particularly T-lymphocyte abnormal-
ities, have been previously implicated in the pathogenesis
of the disease [2]. A suppressed immune response, the ab-
sence of renal histologic alterations on light microscopy,
and no significant immune deposits in glomeruli have
suggested that INS is a T-cell disorder associated with
a functional renal compromise [3]. Proteinuria in INS is
thought to be caused by the effect of circulating cytokines
on glomerular permeability. Thus, several authors have
looked for a cytokine that could render the glomerular
basement membrane more permeable to proteins [2, 3].
Glucocorticoids act by binding to a cytoplasmic GC
receptor, which then translocates to the nucleus to act as
a transcription factor [4]. Previous studies have demon-
strated diminished GC receptor number and binding
affinity in peripheral blood mononuclear cells (PBMC)
from rheumatoid arthritis [8] and asthma SR patients
[9]. In INS patients, there are few GC binding studies
and they are still controversial [10, 11]. Other factors be-
sides GC receptors might mediate the variable response
to GC, such as cytokines [11]. However, there is no con-
sensus concerning the production of several cytokines in
patients with INS [12–15].
In the present study, we evaluated the basal secretion
of plasma and salivary cortisol, the number and affin-
ity of GC receptors, and the pattern of cytokine [tumor
necrosis factor (TNF)-a, interferon (IFN)-c , interleukin
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(IL)-6, IL-10] secretion in control patients and in chil-
dren with INS. In order to classify patients with INS as
SR or SS by the in vitro test, we evaluated dexamethasone
(Dex)-mediated inhibition of concanavalin-A (Con-A)–
stimulated PBMC proliferation. In addition, to evaluate
the role of cytokines in the mechanism of corticosteroid
resistance, we studied the effect of different doses of Dex
on cytokine secretion by Con-A–stimulated PBMC in
culture.
METHODS
Subjects
This prospective study was approved by the institu-
tional review board for human research and informed
consent was obtained from all subjects and their parents.
We studied 11 healthy subjects (6 males, 5 females) rang-
ing in age from 1.2 to 16.2 years, with no signs of acute
or chronic illness and who were taking no drugs. In ad-
dition, we also studied 20 patients with INS (9 males, 11
females) aged 2 to 15.9 years, followed-up by the Division
of Pediatric Nephrology-Faculty of Medicine of Ribeira˜o
Preto, University of Sa˜o Paulo. The diagnostic criteria
for INS were based on the International Study of Kid-
ney Disease in Children [16]. At the time of the study,
all patients had active disease characterized by massive
proteinuria (>40mg/m2/hr or urinary protein/creatinine
ratio >1), with normal serum creatinine levels and who
were not using steroids. Ten patients were off corticos-
teroid therapy for 4 to 40 months (median 16 months).
Ten patients were evaluated during the initial course of
INS and only received corticosteroids after blood and
saliva collection for this study. According to the clini-
cal response to treatment, patients who had complete re-
mission of proteinuria with corticosteroid therapy were
classified as SS (N = 17). Patients who persisted with pro-
teinuria after daily prednisone therapy (60 mg/m2/day)
for 4–6 weeks, followed by high-dose intravenous pulse
methylprednisolone (30 mg/kg/dose, maximum 1000 mg)
on alternate days for 3–6 doses were considered SR
(N = 3). Renal biopsy was performed in the SR patients
and revealed focal segmental glomerulosclerosis in all.
Plasma and salivary cortisol measurement
Blood and saliva samples were obtained from healthy
donors and INS patients between 8:00 and 9:00 a.m.
Serum and salivary cortisol concentrations were mea-
sured by radioimmunoassay, as previously described
[17–19].
Cell preparation
PBMC were isolated by density gradient centrifuga-
tion using Ficoll-Hypaque (Histopaque; Sigma Chemical
Co., St. Louis, MO, USA), washed three times in Hank’s
buffered saline solution (HBSS), and resuspended in
RPMI 1640 (Life Technologies, Gaithersburg, MD, USA)
containing 2 mmol/L HEPES buffer (Sigma Chemi-
cal Co.), 10% fetal calf serum, 100 IU/mL penicillin,
100 g/mL streptomycin, and 10 mg/mL gentamicin.
Binding assay
PBMC Dex-binding assay was performed as previously
described [20]. Cells were suspended in RPMI media and
adjusted to 2 × 106 cells per tube in duplicate and incu-
bated with six concentrations (1.56–50 nmol/L) of Dex
(1, 2, 4, 6, 7, 3H) (Dexamethasone; Amersham Life Sci-
ence, Buckinghamshire, UK) at 37◦C in the presence or
absence of a 1000-fold molar excess of unlabeled Dex
(Dexamethasone; Sigma Chemical Co.) for 1 hour. After
incubation, the cells were washed three times to separate
bound- from free-steroid with 1.5 mL cold phosphate-
buffered saline (PBS) and centrifuged at 400g for 10 min-
utes. After the third wash, the pellets were suspended in
100 lL of RPMI, transferred to vials, and the radioactivity
was counted in a b counter. Specific binding was calcu-
lated by subtracting nonspecific binding from total bind-
ing. Receptor assay data were analyzed by the method
of Scatchard using computerized linear regression anal-
ysis. The binding capacity (Bmax) was expressed as fmol
of dexamethasone bound per mg of protein, and the dis-
sociation constant (Kd), inversely proportional to ligand
affinity, was expressed in nmol/L.
Proliferation and in vitro corticosteroid sensitivity assay
To perform the in vitro steroid sensitivity assay we mea-
sured the inhibitory effect of Dex on Con-A–stimulated
PBMC proliferation. PBMC (2 × 10−6 cells per well)
were plated onto 96-well flat-bottomed plates (Nunc,
Naperville, IL, USA) in triplicate and cultured at 37◦C
in the presence of 5% CO2. Con-A at the dose of
50 lg/mL−1 was used to stimulate the cells in the presence
or absence of different doses (10−8, 10−6, 10−4 mol/L) of
Dex. After 48 hours of culture, the cells were pulsed with 1
lCi/well tritiated thymidine (3H-thymidine, Amersham,
Pharmacia Biotech, UK) for 18 hours before collecting
the supernatants for cytokine quantification. The cells
were harvested with a multiple automated sample har-
vester and radioactivity was counted in a liquid scintilla-
tion b counter (Beckman Coulter, Fullerton, CA, USA).
Percent inhibition of proliferation by steroid was calcu-
lated using the following formula: {1−(x−n/y−n)} 100,
where: x = counts in Dex and Con-A; n = counts in RPMI
alone; y = counts in Con-A alone. The IC50 was defined
as the concentration of Dex that caused a 50% inhibition
of cell proliferation. Subjects with an IC50 >10−6 mol/L
were considered SR. Percent inhibition of cytokine se-
cretion was calculated by the formula above, where x =
cytokine secretion in Dex and Con-A; n = cytokine
secretion in RPMI alone; y = cytokine secretion in Con-
A alone. By using these calculations, the variations for
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Con-A–induced PBMC proliferation, or cytokine secre-
tion occurring between and within individuals at different
times, were compensated.
Cytokine quantification
The supernatants collected during cell culture were
stored at −70◦C for measurement of IL-6, IL-10, TNF-
a, and IFN-c levels by ELISA. The antibodies used
for coating 96-well plates were 18891D (anti-IFN-c ,
PharMingen, San Diego, CA, USA), JES3-19F1 (anti-
IL-10, PharMingen), MAB206 (anti IL-6, R&D Systems,
Minneapolis, MN, USA), and MAB610 (anti-TNF-a,
R&D Systems). Second-step biotinylated detection mon-
oclonal antibodies were 19751N (anti-IFN-c , PharMin-
gen), JES3-12G8 (anti-IL-10, PharMingen), BAF206
(anti-IL-6, R&D Systems), and BAF210 (anti-TNF-a,
R&D Systems). The minimum detection limits for IFN-c ,
IL-10, IL-6, and TNF-a were 78, 78, 3.9, and 7.8 pg/mL,
respectively.
Statistical analysis
All results are expressed as median with 95% CI. Data
were compared using Friedman followed by Dunn test
and Mann-Whitney test, when appropriate, with the level
of significance set at P < 0.05. Due to the small sample
size, the SR patients were analyzed individually.
RESULTS
Plasma and salivary cortisol measurement
Plasma cortisol levels were lower (P = 0.01) in SS pa-
tients (5.4 lg/dL; 95% CI: 4.6–8.3 lg/dL) compared to
normal control patients (8.5 lg/dL; 95% CI: 7.6–12.2 lg/
dL). However, both groups presented similar salivary cor-
tisol concentrations (705 ng/dL; 95% CI: 525–1333 ng/dL
vs. 710 ng/dL; 95% CI: 600–1216 ng/dL, respectively).
Plasma and salivary cortisol levels in patients SR1, SR2,
and SR3 were 7.2, 7.8, 2.0 lg/dL, and 1600, 430, 360 ng/dL,
respectively.
Binding assay
The linearity of the Scatchard plots indicates a sin-
gle class of binding site affinity. The number of binding
sites of GC receptors (Bmax) in PBMC and their apparent
dissociation constant (Kd) were similar in the SS group
(Bmax = 8.3 fmol/mg of protein; 95% CI: 7.2–12.4 fmol/mg
of protein and Kd = 5.5 nmol/L; 95% CI: 3.8–8 nmol/L)
and control patients (Bmax = 8.2 fmol/mg of protein; 95%
CI: 6.4–11.6 fmol/mg of protein and Kd = 3.7 nmol/L;
95% CI: 2.8–5.8 nmol/L). Patient SR2 presented higher
Bmax and Kd (25.5 fmol/mg of protein and 39.8 nmol/L,
respectively) in comparison to the control and SS groups
(Fig. 1). Bmax and Kd in patients SR1 (6.9 fmol/mg of pro-
tein and 4.2 nmol/L) and SR3 (12.9 fmol/mg of protein
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Fig. 1. Representative saturation curves of [3H] dexamethasone bind-
ing to peripheral blood mononuclear cell (PBMC) and the Scatchard
plot (insert) of glucocorticoid receptor (GR) binding studies of a
steroid-sensitive (SS) patient (•), a steroid-resistant (SR2) patient (∆),
and a normal patient ().
and 6.7 nmol/L) were similar to the values of control and
SS patients.
Proliferation assays and sensitive or resistant phenotypes
Basal lymphocyte proliferation was stimulated by Con-
A in the control group (359 cpm; 95% CI: 249–915 cpm
vs. 43,530 cpm; 95% CI: 31,790–58,700 cpm, P = 0.0001)
and SS group (1165 cpm; 95% CI: 790–1584 cpm vs.
39,180 cpm; 95% CI: 35,320–56,830 cpm, P < 0.0001).
Different doses of Dex (10−8, 10−6, 10−4 mol/L) inhibited
lymphocyte proliferation in a dose-dependent manner in
the control group (23,130 cpm, 95% CI: 12,810–35,630
cpm; 11,890 cpm, 95% CI: 4496–16,420 cpm; 10,680 cpm,
95% CI: 3263–12,200 cpm; P < 0.0001) and SS group
(22,440 cpm, 95% CI: 17,410–47,850 cpm; 3366 cpm, 95%
CI: 2666–7092 cpm; 3816 cpm, 95% CI: 3377–6851 cpm;
P < 0.0001). The steroid-resistant INS patients also pre-
sented lymphocyte proliferation after Con-A stimulation
(SR1, 2009 vs. 60,847 cpm; SR2, 318 vs. 15,899 cpm; SR3,
369 vs. 30,428 cpm). Lymphocyte proliferation after dif-
ferent doses of Dex (10−8, 10−6, 10−4 mol/L) was 42,405,
9709, and 18,382 cpm; 11,462, 8578, and 8339 cpm; 29,167,
28,830, and 24,158 cpm for patients SR1, SR2, and SR3,
respectively. Using the IC50 to classify patients by in vitro
test as SR or SS, we observed that all control patients, all
clinically SS patients, and one clinically SR patient (SR1)
presented more than 50% inhibition of PBMC prolifer-
ation with Dex 10−6 mol/L. Patients SR2 and SR3, clin-
ically classified as SR, were also resistant by the in vitro
test (IC50 >10−6 mol/L). Figure 2 shows the percentage
of inhibition of lymphocyte proliferation after incubation
in RPMI with Con-A plus different doses of Dex (10−8,
10−6, and 10−4 mol/L) in control, SS, and SR patients.
Using a low dose (10−8 mol/L) of Dex, there was a signif-
icant difference in the percentage of suppression in vitro
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Fig. 2. Percentage of inhibition of lymphocyte proliferation after in-
cubation in RPMI with concanavalin-A (Con-A) plus different doses
of dexamethasone (10−8, 10−6, and 10−4 mol/L) in healthy control
patients, steroid-sensitive (SS) patients (•), and steroid-resistant (SR)
patients: SR1 (), SR2 (∆), SR3 (). Boxes indicate the 95% CI in
control patients.
between the control (58%; 95% CI: 39–70) and SS (33%;
95% CI: 21–43) groups (P = 0.02).
Cytokines
Cytokine levels were measured in the supernatant col-
lected from fresh cultured PBMC in the basal condition
and after stimulation with Con-A alone or Con-A plus
different doses of Dex in control, SS, and SR patients.
There was no difference in basal production of IL-6,
IL-10, IFN-c , or TNF-a between the control and
SS groups. Con-A–stimulated PBMC increased IFN-c ,
TNF-a, IL-10, and IL-6 secretion significantly compared
with the basal production in the control (P < 0.005) and
SS (P < 0.0001) groups. The percentage of inhibition of
TNF-a, IFN-c , IL-6, and IL-10 secretion after different
doses of Dex in the control, SS, and SR patients are shown
in Figure 3. The secretion of IFN-c , TNF-a, and IL-6 was
significantly inhibited by Dex 10−6 mol/L in the control
(P < 0.01) and SS (P < 0.001) groups. IL-10 secretion was
significantly inhibited by Dex 10−6 mol/L in the SS group
(P < 0.001). However, in the control group, a higher dose
of Dex (10−4 mol/L) was required to significantly inhibit
IL-10 secretion (P < 0.001). In SR2 and SR3 patients,
the levels of cytokines increased after Con-A stimula-
tion, but remained elevated even after a high dose of Dex
(10−4 mol/L).
DISCUSSION
Glucocorticoids are crucial mediators of the endocrine-
immune interaction and play an important role in modu-
lating cellular and humoral immune responses [21, 22].
An imbalance on the immune-hypothalamic-pituitary-
adrenal (HPA) axis may be involved in inflammatory dis-
eases, such as asthma [9], rheumatoid arthritis [8], and
INS. Thus, we hypothesized that GC might be important
not only to the treatment, but also to the pathogenesis of
INS. In the present study, we demonstrated that plasma
cortisol levels were decreased in INS patients compared
to normal control patients, which may be explained by
the lower concentration of plasma proteins during the
active phase of the disease. Indeed, salivary cortisol con-
centrations, which are unaffected by the concentration of
plasma proteins and reflect the biologically active serum
unbound cortisol levels [23], were similar in INS patients
and normal control patients, suggesting that endogenous
cortisol secretion is preserved in INS.
We also evaluated the number of binding sites and
affinity of GC receptors in patients with INS and healthy
control patients. There was no difference in the number
and affinity of GC receptors in PBMC of SS patients
compared to control patients. Among SR patients, the
number and affinity of GC receptors were variable. A
former study [10] including patients with different causes
of nephrotic syndrome demonstrated that the number of
GC receptors was increased in SS patients and decreased
in SR patients. In contrast, Haack et al [11] showed no
change in the density and binding affinity of GC recep-
tors in SR INS patients, which were off steroid therapy
for a median time of 5 months. The use of corticosteroids
has been shown to influence the expression of GC recep-
tors, causing down-regulation of the receptors in cells [24,
25]. Taken together, these data suggest that GC receptors
might mediate glucocorticoid resistance in some patients
with INS. It is also important to point out that binding
assays evaluate the GC receptor a, which is the classic
ligand-binding protein for corticosteroid. Therefore, we
cannot rule out an overexpression of GC receptor b , a
dominant negative inhibitor of GC receptor a, inducing
steroid insensitivity in INS, as well established for asth-
matic patients [26, 27].
In an attempt to identify predictive factors of the
response to GC in INS, we evaluated the pattern of
Dex-mediated inhibition of Con-A–stimulated PBMC
proliferation. Using the IC50 to classify patients by in vitro
study, our data showed that all clinically SS patients pre-
sented more than 50% inhibition of PBMC proliferation
with Dex 10−6 mol/L. However, there was a significant
difference in the percentage of suppression in vitro be-
tween the control and SS groups using a low dose of Dex
(10−8 mol/L), indicating a diminished sensitivity to corti-
costeroids even in SS patients. In addition, patients SR2
and SR3 presented both in vivo and in vitro resistance
to GC, whereas patient SR1 responded to Dex in vitro
but had a poor clinical response to GC in vivo. This raises
questions about compliance to therapy or the presence
of mutations in genes that encode proteins of the slit di-
aphragm of the glomerular basement membrane, such as
podocin and nephrin, as recently described [28, 29]. Al-
though we have studied a limited number of SR patients
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Fig. 3. Percentage of inhibition of inter-
feron (IFN)-c and tumor necrosis factor
(TNF)-a (A), and interleukin (IL)-10 and
IL-6 (B) cytokine secretion after periph-
eral blood mononuclear cell (PBMC) incuba-
tion in RPMI with concanavalin-A (Con-A)
plus different doses of dexamethasone (10−8,
10−6, and 10−4 mol/L) in healthy control pa-
tients, steroid-sensitive (SS) patients (•), and
steroid-resistant (SR) patients: SR1 (), SR2
(∆), SR3 (). Boxes indicate the 95% CI in
control patients.
with a rare disease, these results set the path for future
analysis.
A shift in the balance of Th1 and Th2 cytokine response
has been related to the development of autoimmune dis-
eases or atopic reactions [30, 31, 32]. Moreover, abnor-
mal cytokine release has been studied to investigate the
primary insult in INS [12–15]. Studies evaluating serum
cytokines have demonstrated a shift to Th1 pattern in pa-
tients with focal segmental glomerulosclerosis unrespon-
sive to steroids [13]. In addition, children with INS during
relapses presented elevated serum Th1 cytokines, while
long-term remission appeared to be related to increased
Th2 cytokine production down-regulating Th1 cytokines
[14]. In the present study, basal- and Con-A–stimulated
levels of IFN-c , TNF-a, IL-6, and IL-10 were similar in
control, SS, and SR patients. Our results are in contrast
to those observed by Stachowski et al [12], who demon-
strated a predominance of Th2 activity in patients with SS
INS and Th1 cytokines in SR INS patients. The conflicting
results might be explained by the different lymphocyte
stimuli used in both studies, Con-A–stimulated PBMC
versus tetanus toxoid–stimulated CD4+ T-cell, and also
by the ability of both T-cell subsets to produce pro- and
anti-inflammatory cytokines. Finally, the main immuno-
logic abnormality in INS may not lie only in T-helper
cells, but also in other cells such as suppressor/cytotoxic
T-cells, natural killer cells, or monocytes/macrophages.
Indeed, it has been shown that lymphocytes and mono-
cytes are able to decrease human glomerular epithelial
cell glycosaminoglycans, leading to the loss of polyanion
charge of the glomerular basement membrane, the major
cause of proteinuria in INS [33, 34].
To our knowledge there is no data in the literature
evaluating the effect of dose-response of Dex in PBMC-
stimulated cytokine production in INS. In our study,
Con-A–stimulated IFN-c , TNF-a, and IL-6 were signif-
icantly inhibited by Dex 10−6 mol/L in the control and
SS groups. IL-10 presented the same inhibition pattern
in SS patients; however, the control group required Dex
10−4 mol/L to significantly inhibit IL-10 secretion. In-
deed, there is evidence suggesting that IL-10 increases
the sensitivity of human monocytes to Dex, potentially
regulating GC receptor expression or inhibiting nuclear
factor kappa B (NF-jB) activation [35]. On the other
hand, PBMC cytokine secretion from SR patients were
increased after Con-A stimulation and remained elevated
even after high doses of Dex, reflecting a disturbed im-
mune regulation that might contribute to corticosteroid
resistance in INS. Recently, unresolved acute respira-
tory distress syndrome has also been associated with sys-
temic inflammation–induced glucocorticoid resistance.
The authors suggest failure of endogenous glucocorticoid
in the control of inflammation, with resolution of both
systemic inflammation and peripheral acquired glucocor-
ticoid resistance after prolonged corticosteroid adminis-
tration [36].
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CONCLUSION
Our data showed that INS patients have a preserved
endogenous cortisol secretion, but they present a spec-
trum of glucocorticoid sensitivity, ranging from dimin-
ished sensitivity in SS patients to resistance in SR patients,
compared with control patients. Although SR nephrotic
syndrome represents a heterogeneous group of kidney
diseases, the present data also suggest that the clinical
response to corticosteroid therapy of patients with INS
can be predicted accurately using an in vitro test of GC
suppression of Con-A–induced cell proliferation. Finally,
abnormalities of number and affinity of the GC recep-
tor and altered secretion of cytokines may be involved in
tissue sensitivity to corticosteroids in INS patients.
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